A Phase 1 interventional study of ALIA-1758 and Placebo in Alzheimer Disease, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Alzheimer Disease by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · AbbVie.
Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 17th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 1, and was the 26th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 27 studies in Alzheimer Disease by AbbVie is open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, China
Ages 50–90
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 3 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 210 across the 27 interventional studies. Of the 24 that completed or were terminated, 6 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Alzheimer Disease by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Ascending Dose (SAD) cohorts
Drug: ALIA-1758
Single Ascending Dose (SAD) cohorts
Other: Placebo
Intravenous or subcutaneous doses
Intravenous or subcutaneous doses
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)
Time frame: Up to 85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Cmax
Cmax
Time frame: 0-85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: T1/2
elimination half-life (T1/2)
Time frame: 0-85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: AUC
Area Under Curve (AUC)
Time frame: 0-85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Bioavailability
Bioavailability after SC administration (F)
Time frame: 0-85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Clearance
Clearance (CL)
Time frame: 0-85 days after dosing
Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Volume of distribution
Volume of distribution (Vz)
Time frame: 0-85 days after dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Apr 2025, 11 months.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.